📊 AORT Key Takeaways
Is Artivion, Inc.. (AORT) a Good Investment?
Artivion demonstrates solid revenue growth of 13.6% YoY and maintains a healthy balance sheet with strong liquidity (3.53x current ratio), but profitability concerns are evident with deteriorating net margins (2.2%) and anemic free cash flow (0.2% FCF margin). The dramatic EPS growth masks underlying weakness in operational efficiency and cash generation, suggesting the company is struggling to convert top-line growth into sustainable bottom-line profitability.
Artivion shows solid top-line momentum and strong gross profitability, indicating healthy demand and product economics. However, that growth is not yet translating into strong bottom-line or cash-flow performance, with thin net margins, weak returns on capital, minimal free cash flow, and limited interest coverage constraining financial flexibility. The fundamentals support a neutral view until operating leverage and cash conversion improve more clearly.
Why Buy Artivion, Inc.. Stock? AORT Key Strengths
- Strong revenue growth of 13.6% YoY indicating solid market demand in surgical instruments sector
- Excellent liquidity position with 3.53x current ratio and 2.62x quick ratio providing operational flexibility
- Conservative debt levels with 0.48x debt-to-equity ratio and moderate leverage profile
- Revenue growth of 13.6% YoY indicates strong commercial momentum
- Gross margin of 64.4% suggests attractive product mix and pricing power
- Liquidity is solid, with a 3.53x current ratio and manageable debt/equity of 0.48x
AORT Stock Risks: Artivion, Inc.. Investment Risks
- Severe cash conversion problem with free cash flow of only $839K (0.2% margin) despite $39.9M operating cash flow, indicating capital intensity issues
- Low net profitability of 2.2% and declining operational efficiency with net income growth of only 0.1% YoY despite 13.6% revenue growth
- Dangerously low interest coverage of 1.4x with $215.1M long-term debt creates vulnerability to rising rates or earnings deterioration
- Net margin of 2.2% and ROE of 2.2% show weak earnings quality relative to sales growth
- Free cash flow is near breakeven, limiting internally funded reinvestment and debt reduction
- Interest coverage of 1.4x leaves little cushion if financing costs stay elevated or earnings soften
Key Metrics to Watch
- Free cash flow conversion and capital expenditure trends as the 1:1 ratio of CapEx to OCF is unsustainable
- Gross margin sustainability at 64.4% to confirm pricing power and cost management in competitive medical device market
- Operating leverage improvement to narrow the gap between gross profit growth and net income growth
- Operating margin expansion and interest coverage improvement
- Free cash flow generation relative to revenue growth
Artivion, Inc.. (AORT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 0.2% FCF margin may limit capital allocation flexibility. Strong liquidity with a 3.53x current ratio provides a solid financial cushion.
AORT Profit Margin, ROE & Profitability Analysis
AORT vs Healthcare Sector: How Artivion, Inc.. Compares
How Artivion, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Artivion, Inc.. Stock Overvalued? AORT Valuation Analysis 2026
Based on fundamental analysis, Artivion, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Artivion, Inc.. Balance Sheet: AORT Debt, Cash & Liquidity
AORT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Artivion, Inc..'s revenue has grown significantly by 48% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.75 indicates the company is currently unprofitable.
AORT Revenue Growth, EPS Growth & YoY Performance
AORT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $95.8M | -$2.3M | $-0.05 |
| Q2 2025 | $98.0M | $840.0K | $0.02 |
| Q1 2025 | $97.4M | -$505.0K | $-0.01 |
| Q3 2024 | $87.9M | -$2.3M | $-0.05 |
| Q2 2024 | $89.3M | -$2.1M | $-0.05 |
| Q1 2024 | $83.2M | $7.5M | $0.18 |
| Q3 2023 | $76.8M | -$9.8M | $-0.24 |
| Q2 2023 | $80.3M | -$3.4M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Artivion, Inc.. Dividends, Buybacks & Capital Allocation
AORT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Artivion, Inc.. (CIK: 0000784199)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 1, 2026 | DEF 14A | artivion-def14a_051226.htm | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772668477.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772668382.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772668260.xml | View → |
| Mar 4, 2026 | 4 | xslF345X05/wk-form4_1772668162.xml | View → |
❓ Frequently Asked Questions about AORT
What is the AI rating for AORT?
Artivion, Inc.. (AORT) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AORT's key strengths?
Claude: Strong revenue growth of 13.6% YoY indicating solid market demand in surgical instruments sector. Excellent liquidity position with 3.53x current ratio and 2.62x quick ratio providing operational flexibility. ChatGPT: Revenue growth of 13.6% YoY indicates strong commercial momentum. Gross margin of 64.4% suggests attractive product mix and pricing power.
What are the risks of investing in AORT?
Claude: Severe cash conversion problem with free cash flow of only $839K (0.2% margin) despite $39.9M operating cash flow, indicating capital intensity issues. Low net profitability of 2.2% and declining operational efficiency with net income growth of only 0.1% YoY despite 13.6% revenue growth. ChatGPT: Net margin of 2.2% and ROE of 2.2% show weak earnings quality relative to sales growth. Free cash flow is near breakeven, limiting internally funded reinvestment and debt reduction.
What is AORT's revenue and growth?
Artivion, Inc.. reported revenue of $441.3M.
Does AORT pay dividends?
Artivion, Inc.. pays dividends, with $3.4M distributed to shareholders in the trailing twelve months.
Where can I find AORT SEC filings?
Official SEC filings for Artivion, Inc.. (CIK: 0000784199) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AORT's EPS?
Artivion, Inc.. has a diluted EPS of $0.21.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AORT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Artivion, Inc.. has a HOLD rating with 69% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AORT stock overvalued or undervalued?
Valuation metrics for AORT: ROE of 2.2% (sector avg: 15%), net margin of 2.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AORT stock in 2026?
Our dual AI analysis gives Artivion, Inc.. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AORT's free cash flow?
Artivion, Inc..'s operating cash flow is $39.9M, with capital expenditures of $39.0M. FCF margin is 0.2%.
How does AORT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 2.2% (avg: 12%), ROE 2.2% (avg: 15%), current ratio 3.53 (avg: 2).